Today: 21 May 2026
RIOT stock jumps after Riot Platforms names new CFO and ties bonuses to data-center deals
4 January 2026
2 mins read

RIOT stock jumps after Riot Platforms names new CFO and ties bonuses to data-center deals

NEW YORK, January 3, 2026, 19:17 ET — Market closed

  • Riot Platforms shares rose about 12% in the last U.S. session, closing at $14.16.
  • The bitcoin miner said Jason Chung will become CFO on March 1, replacing Colin Yee, who will move into a senior advisor role.
  • A filing showed Riot removed a bitcoin-focused metric from its 2026 incentive plan and added data-center revenue and NOI measures once it secures a tenant.

Riot Platforms shares rose $1.52, or nearly 12%, in the most recent U.S. session, ending Friday at $14.16. The move followed the bitcoin miner’s announcement of a chief financial officer transition and a revamp of executive incentives toward data-center development.

The developments matter now because miners are trying to convince investors they can turn power-heavy campuses into steadier cash generators by leasing space and electricity to data-center customers. Riot’s latest filing explicitly ties management pay to that strategy, a signal investors often read as a marker of corporate priorities.

Riot said Jason Chung, currently its executive vice president and head of corporate development and strategy, will become CFO on March 1. Colin Yee will remain CFO until then and then shift to a senior advisor role, the company said.

“His extensive experience and solid track record of delivering value-creating results … make him the ideal leader to guide our capital allocation strategy,” CEO Jason Les said. Riot Platforms

A Form 8-K showed Yee agreed to serve as senior advisor through January 2028, with an annual base fee of $500,000 for the first 12 months after the transition, then $20,000 per month, plus $2 million worth of restricted stock units.

The same filing detailed broader pay and incentive changes effective Jan. 1, including raising base salaries for Les and executive chairman Benjamin Yi to $900,000 from $600,000 and removing a bitcoin component from their base compensation.

Riot also amended its 2026 annual incentive plan — its cash bonus scorecard — to eliminate a metric called “Bitcoin Yield.” It said it will add two data-center measures once a tenant is secured: “data center revenue” and “Data Center NOI,” or net operating income, a profit measure that subtracts operating costs from revenue. SEC

Under the redesign, data-center revenue and NOI would each carry 15% weighting, while adjusted EBITDA — profit before interest, taxes, depreciation and amortization — is reduced to 25% at target, the filing showed. Payouts range from zero to as much as 200% of target.

The stock move came alongside a firmer crypto backdrop: bitcoin was last up about 1.6% at roughly $91,356. Other U.S.-listed miners also rose sharply on Friday, with Marathon Digital up about 10%, CleanSpark up about 14% and Hut 8 up nearly 12%.

Traders often treat miners as leveraged plays on bitcoin, meaning the shares tend to amplify moves in the cryptocurrency. Riot’s additional swing factor is execution: the filing says the data-center metrics apply only “upon securing a data center tenant.” SEC

Before U.S. markets reopen on Monday, Jan. 5, investors will watch bitcoin’s weekend move and whether RIOT holds Friday’s breakout. The shares traded between $12.66 and $14.39 in the session, levels that can serve as near-term support and resistance.

Looking further out, third-party earnings calendars such as Zacks and MarketBeat estimate Riot’s next quarterly report around Feb. 23, though the company has not announced a date. The next update on capital spending, funding plans and any progress on data-center leasing is likely to set the tone for the stock.

Stock Market Today

  • Teradyne, Kulicke and Soffa, Impinj, Microchip, IPG Photonics Stocks Slide on U.S.-China Semiconductor Summit Outcome
    May 21, 2026, 2:58 AM EDT. Shares of Teradyne, Kulicke and Soffa, Impinj, Microchip Technology, and IPG Photonics dropped sharply following the U.S.-China summit, which ended without key breakthroughs on semiconductor exports. Expectations for U.S. approval of Nvidia's H200 chip shipments to China were unmet, disappointing investors. U.S. Trade Representative Jamieson Greer indicated semiconductors were not a negotiation focus, dampening near-term optimism. Despite the sell-off, IPG Photonics' stock, known for volatility, remains down significantly from its 52-week high but has gained 34.3% year-to-date. Market reactions highlight cautious sentiment amid geopolitical tensions, with analysts skeptical about swift comprehensive deals due to national security concerns.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Bloom Energy stock jumps 14% to start 2026 as fuel-cell names rebound — what investors watch next
Previous Story

Bloom Energy stock jumps 14% to start 2026 as fuel-cell names rebound — what investors watch next

Spyre Therapeutics stock slides 6.6% after New Year session; $30 level and 2026 trial data in focus
Next Story

Spyre Therapeutics stock slides 6.6% after New Year session; $30 level and 2026 trial data in focus

Go toTop